Day One Biopharmaceuticals, Inc. (DAWN)

NASDAQ: DAWN · IEX Real-Time Price · USD

15.38

+0.42 (2.81%)

At close: Apr 22, 2024, 4:00 PM

15.67

+0.29 (1.89%)

After-hours: Apr 22, 2024, 7:57 PM EDT

DAWN Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	75.54	61.29	29.16	4.68	1.01
Research & Development	130.52	85.62	43.58	9.1	13.9
Operating Expenses	206.06	146.91	72.74	13.78	14.91
Operating Income	-206.06	-146.91	-72.74	-13.78	-14.91
Interest Expense / Income	0	0	0	0.03	2.08
Other Expense / Income	-17.15	-4.73	97.9	26.7	0
Pretax Income	-188.92	-142.18	-170.64	-40.51	-16.98
Net Income	-188.92	-142.18	-170.64	-40.51	-16.98
Preferred Dividends	0	0	0	0	-4.35
Net Income Common	-188.92	-142.18	-170.64	-40.51	-12.63
Shares Outstanding (Basic)	80	65	37	6	6
Shares Outstanding (Diluted)	80	65	37	6	6
Shares Change	21.85%	77.13%	568.42%	-6.67%	-
EPS (Basic)	-2.37	-2.17	-4.62	-7.33	-2.13
EPS (Diluted)	-2.37	-2.17	-4.62	-7.33	-2.13
Free Cash Flow	-147.08	-109.9	-48.54	-13.58	-4.52
Free Cash Flow Per Share	-1.84	-1.68	-1.31	-2.46	-0.76
EBITDA	-188.53	-141.65	-170.44	-40.32	-14.91
Depreciation & Amortization	0.38	0.53	0.2	0.16	0
EBIT	-188.92	-142.18	-170.64	-40.48	-14.91

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).